{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:59:35Z","timestamp":1786121975031,"version":"build-2736575974"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-026-10663-x","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T07:08:04Z","timestamp":1786086484000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Iron overload cardiomyopathy"],"prefix":"10.1007","volume":"31","author":[{"given":"Georgios","family":"Papingiotis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Mantzourani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Gogas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Farmakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"10663_CR1","doi-asserted-by":"publisher","first-page":"18016","DOI":"10.1038\/nrdp.2018.16","volume":"4","author":"P Brissot","year":"2018","unstructured":"Brissot P, Pietrangelo A, Adams PC, de Graaff B, McLaren CE (2018) Lor\u00e9al O. Haemochromatosis. Nat Rev Dis Primers 4:18016","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10663_CR2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/ejhf.708","volume":"19","author":"D Farmakis","year":"2017","unstructured":"Farmakis D, Triposkiadis F, Lekakis J, Parissis J (2017) Heart failure in haemoglobinopathies: pathophysiology, clinical phenotypes, and management. Eur J Heart Fail 19(4):479\u2013489","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10663_CR3","first-page":"1187","volume":"89","author":"C Borgna-Pignatti","year":"2004","unstructured":"Borgna-Pignatti C, Rugolotto S, De Stefano P et al (2004) Survival and complications in patients with thalassaemia major treated with transfusion and deferoxamine. Haematologica 89(10):1187\u20131193","journal-title":"Haematologica"},{"issue":"1","key":"10663_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1532-429X-10-42","volume":"10","author":"B Modell","year":"2008","unstructured":"Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ (2008) Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson 10(1):42","journal-title":"J Cardiovasc Magn Reson"},{"key":"10663_CR5","volume-title":"Guidelines for the Management of Transfusion-Dependent \u03b2-Thalassaemia (TDT)","author":"M Walker","year":"2025","unstructured":"Walker M, Farmakis D (2025) Cardiovascular Disease. In: Taher AT, Farmakis D, Porter JB, Cappellini MD, Musallam KM (eds) Guidelines for the Management of Transfusion-Dependent \u03b2-Thalassaemia (TDT), 5th edn. Thalassaemia International Federation, Nicosia, Cyprus","edition":"5"},{"issue":"8","key":"10663_CR6","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.14309\/ajg.0000000000000315","volume":"114","author":"KV Kowdley","year":"2019","unstructured":"Kowdley KV, Brown KE, Ahn J, Sundaram V (2019) ACG Clinical Guideline: Hereditary Haemochromatosis. Am J Gastroenterol 114(8):1202\u20131218","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10663_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10554-023-02973-0","volume":"40","author":"P Cort\u00e9s","year":"2024","unstructured":"Cort\u00e9s P, Elsayed AA, Stancampiano FF et al (2024) Clinical and genetic predictors of cardiac dysfunction assessed by echocardiography in patients with hereditary haemochromatosis. Int J Cardiovasc Imaging 40(1):45\u201353","journal-title":"Int J Cardiovasc Imaging"},{"key":"10663_CR8","volume-title":"Guidelines for the Management of Transfusion-Dependent \u03b2-Thalassaemia (TDT)","author":"JB Porter","year":"2025","unstructured":"Porter JB, Wood JC, Coates TD (2025) Iron Overload and Chelation. In: Taher AT, Farmakis D, Porter JB et al (eds) Guidelines for the Management of Transfusion-Dependent \u03b2-Thalassaemia (TDT), 5th edn. Thalassaemia International Federation, Nicosia, Cyprus","edition":"5"},{"issue":"8","key":"10663_CR9","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMra2021838","volume":"384","author":"AT Taher","year":"2021","unstructured":"Taher AT, Musallam KM, Cappellini MD (2021) \u03b2-Thalassaemias. N Engl J Med 384(8):727\u2013743","journal-title":"N Engl J Med"},{"issue":"10343","key":"10663_CR10","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1016\/S0140-6736(22)00536-0","volume":"399","author":"A Kattamis","year":"2022","unstructured":"Kattamis A, Kwiatkowski JL, Aydinok Y, Thalassaemia (2022) Lancet 399(10343):2310\u20132324","journal-title":"Lancet"},{"issue":"4","key":"10663_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1182\/blood.2023022501","volume":"145","author":"HA Leitch","year":"2025","unstructured":"Leitch HA, Buckstein R (2025) How I treat iron overload in adult MDS. Blood 145(4):383\u2013396","journal-title":"Blood"},{"key":"10663_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ijcard.2021.07.060","volume":"342","author":"K Udani","year":"2021","unstructured":"Udani K, Chris-Olaiya A, Ohadugha C, Malik A, Sansbury J, Paari D (2021) Cardiovascular manifestations in hospitalized patients with haemochromatosis in the United States. Int J Cardiol 342:117\u2013124","journal-title":"Int J Cardiol"},{"key":"10663_CR13","doi-asserted-by":"publisher","first-page":"k5222","DOI":"10.1136\/bmj.k5222","volume":"364","author":"LC Pilling","year":"2019","unstructured":"Pilling LC, Tamosauskaite J, Jones G et al (2019) Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK Biobank. BMJ 364:k5222","journal-title":"BMJ"},{"key":"10663_CR14","doi-asserted-by":"publisher","first-page":"e079147","DOI":"10.1136\/bmj-2023-079147","volume":"387","author":"M Mottelson","year":"2024","unstructured":"Mottelson M, Helby J, Nordestgaard BG et al (2024) Mortality and risk of diabetes, liver disease, and heart disease in individuals with haemochromatosis HFE C282Y homozygosity and normal concentrations of iron, transferrin saturation, or ferritin. BMJ 387:e079147","journal-title":"BMJ"},{"key":"10663_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3389\/fphar.2014.00045","volume":"5","author":"ZI Cabantchik","year":"2014","unstructured":"Cabantchik ZI (2014) Labile iron in cells and body fluids: physiology, pathology, and pharmacology. Front Pharmacol 5:45","journal-title":"Front Pharmacol"},{"issue":"9","key":"10663_CR16","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/nm920","volume":"9","author":"GY Oudit","year":"2003","unstructured":"Oudit GY, Sun H, Trivieri MG et al (2003) L-type Ca2 + channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med 9(9):1187\u20131194","journal-title":"Nat Med"},{"issue":"2","key":"10663_CR17","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1600-0609.2010.01549.x","volume":"88","author":"S Kumfu","year":"2011","unstructured":"Kumfu S, Chattipakorn S, Srichairatanakool S, Settakorn J, Fucharoen S, Chattipakorn N (2011) T-type calcium channel as a portal of iron uptake into cardiomyocytes of beta-thalassemic mice. Eur J Haematol 88(2):156\u2013166","journal-title":"Eur J Haematol"},{"issue":"2","key":"10663_CR18","doi-asserted-by":"publisher","first-page":"107886","DOI":"10.1016\/j.celrep.2020.107886","volume":"32","author":"JW Rhee","year":"2020","unstructured":"Rhee JW, Yi H, Thomas D et al (2020) Modeling secondary iron overload cardiomyopathy with human induced pluripotent stem cell-derived cardiomyocytes. Cell Rep 32(2):107886","journal-title":"Cell Rep"},{"issue":"1","key":"10663_CR19","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.cmet.2015.05.002","volume":"22","author":"S Jenkitkasemwong","year":"2015","unstructured":"Jenkitkasemwong S, Wang CY, Coffey R et al (2015) SLC39A14 is required for the development of hepatocellular iron overload in murine models of hereditary haemochromatosis. Cell Metab 22(1):138\u2013150","journal-title":"Cell Metab"},{"key":"10663_CR20","doi-asserted-by":"crossref","unstructured":"Kumfu S, Fucharoen S, Chattipakorn SC, Chattipakorn N (2022) Iron overload cardiomyopathy: Using the latest evidence to inform future applications. Exp Cell Res","DOI":"10.1177\/15353702221076397"},{"issue":"3","key":"10663_CR21","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1161\/CIRCRESAHA.122.321667","volume":"132","author":"KT Sawicki","year":"2023","unstructured":"Sawicki KT, De Jesus A, Ardehali H (2023) Iron metabolism in cardiovascular disease: physiology, mechanisms, and therapeutic targets. Circ Res 132(3):379\u2013396","journal-title":"Circ Res"},{"issue":"6","key":"10663_CR22","doi-asserted-by":"publisher","first-page":"867","DOI":"10.3390\/cells12060867","volume":"12","author":"AM Fratta Pasini","year":"2023","unstructured":"Fratta Pasini AM, Stranieri C, Busti F, Di Leo EG, Girelli D, Cominacini L (2023) New insights into the role of ferroptosis in cardiovascular diseases. Cells 12(6):867","journal-title":"Cells"},{"issue":"20","key":"10663_CR23","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1161\/CIRCULATIONAHA.111.050773","volume":"124","author":"DT Kremastinos","year":"2011","unstructured":"Kremastinos DT, Farmakis D (2011) Iron overload cardiomyopathy in clinical practice. Circulation 124(20):2253\u20132263","journal-title":"Circulation"},{"issue":"6","key":"10663_CR24","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1007\/s00330-020-06668-1","volume":"30","author":"A Meloni","year":"2020","unstructured":"Meloni A, Pistoia L, Positano V et al (2020) CMR for myocardial iron overload quantification: calibration curve from the MIOT Network. Eur Radiol 30(6):3217\u20133225","journal-title":"Eur Radiol"},{"issue":"5","key":"10663_CR25","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR et al (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149(5):1060\u20131072","journal-title":"Cell"},{"issue":"3","key":"10663_CR26","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/cvr\/cvag019","volume":"122","author":"KI Karampinos","year":"2026","unstructured":"Karampinos KI, Farmakis D, Gurung R, Foo RSY, Filippatos GS, Cokkinos DV (2026) Ferroptosis in heart failure: from molecular insights to therapeutic implications. Cardiovasc Res 122(3):313\u2013335","journal-title":"Cardiovasc Res"},{"issue":"7","key":"10663_CR27","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1073\/pnas.1821022116","volume":"116","author":"X Fang","year":"2019","unstructured":"Fang X, Wang H, Han D et al (2019) Ferroptosis as a target for protection against cardiomyopathy. Proc Natl Acad Sci USA 116(7):2672\u20132680","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7784","key":"10663_CR28","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41586-019-1705-2","volume":"575","author":"K Bersuker","year":"2019","unstructured":"Bersuker K, Hendricks JM, Li Z et al (2019) The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature 575(7784):688\u2013692","journal-title":"Nature"},{"issue":"7784","key":"10663_CR29","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-019-1707-0","volume":"575","author":"S Doll","year":"2019","unstructured":"Doll S, Freitas FP, Shah R et al (2019) FSP1 is a glutathione-independent ferroptosis suppressor. Nature 575(7784):693\u2013698","journal-title":"Nature"},{"issue":"7860","key":"10663_CR30","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41586-021-03539-7","volume":"593","author":"C Mao","year":"2021","unstructured":"Mao C, Liu X, Zhang Y et al (2021) DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature 593(7860):586\u2013590","journal-title":"Nature"},{"key":"10663_CR31","doi-asserted-by":"crossref","unstructured":"Karampinos KI, Georgiopoulos G, Kallikourdis M, Gurung R, Foo R, Cokkinos DV, Farmakis D (2026) Ferroptosis-associated fibroblast activation and transcriptional remodelling in human heart failure: a proof-of-concept study. Eur J Clin Invest. (in press).","DOI":"10.1111\/eci.70213"},{"key":"10663_CR32","doi-asserted-by":"publisher","first-page":"116727","DOI":"10.1016\/j.taap.2023.116727","volume":"479","author":"S Kumfu","year":"2023","unstructured":"Kumfu S, Sripetchwandee J, Thonusin C et al (2023) Ferroptosis inhibitor improves cardiac function more effectively than inhibitors of apoptosis and necroptosis through cardiac mitochondrial protection in rats with iron-overloaded cardiomyopathy. Toxicol Appl Pharmacol 479:116727","journal-title":"Toxicol Appl Pharmacol"},{"key":"10663_CR33","first-page":"916","volume":"36","author":"RM Bell","year":"2015","unstructured":"Bell RM, Mohamed SA, Ako E et al (2015) The prevalence and risk factors for atrial fibrillation in beta-thalassaemia major. Eur Heart J 36:916","journal-title":"Eur Heart J"},{"issue":"9","key":"10663_CR34","doi-asserted-by":"publisher","first-page":"5566","DOI":"10.19102\/icrm.2023.14095","volume":"14","author":"W Abdelmottaleb","year":"2023","unstructured":"Abdelmottaleb W, Maraey O, Ozbay M et al (2023) Association between beta-thalassaemia and atrial fibrillation. J Innov Card Rhythm Manag 14(9):5566\u20135569","journal-title":"J Innov Card Rhythm Manag"},{"issue":"2","key":"10663_CR35","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/jmri.20379","volume":"22","author":"MA Westwood","year":"2005","unstructured":"Westwood MA, Wonke B, Maceira AM et al (2005) Left ventricular diastolic function compared with T2* cardiovascular magnetic resonance for early detection of myocardial iron overload in thalassaemia major. J Magn Reson Imaging 22(2):229\u2013233","journal-title":"J Magn Reson Imaging"},{"issue":"3","key":"10663_CR36","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1161\/CIRCHEARTFAILURE.109.913863","volume":"3","author":"DT Kremastinos","year":"2010","unstructured":"Kremastinos DT, Farmakis D, Aessopos A et al (2010) \u03b2-Thalassaemia cardiomyopathy: history, present considerations, and future perspectives. Circ Heart Fail 3(3):451\u2013458","journal-title":"Circ Heart Fail"},{"issue":"1","key":"10663_CR37","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1161\/01.CIR.91.1.66","volume":"91","author":"DT Kremastinos","year":"1995","unstructured":"Kremastinos DT, Tiniakos G, Theodorakis GN, Katritsis DG, Toutouzas PK (1995) Myocarditis in beta-thalassaemia major: a cause of heart failure. Circulation 91(1):66\u201371","journal-title":"Circulation"},{"issue":"4","key":"10663_CR38","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1532\/IJH97.E0532","volume":"83","author":"M Tsironi","year":"2006","unstructured":"Tsironi M, Korovesis K, Farmakis D, Deftereos S, Aessopos A (2006) Hypocalcemic heart failure in thalassemic patients. Int J Hematol 83(4):314\u2013317","journal-title":"Int J Hematol"},{"issue":"9","key":"10663_CR39","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1182\/blood.V92.9.3455","volume":"92","author":"E Economou-Petersen","year":"1998","unstructured":"Economou-Petersen E, Aessopos A, Kladi A et al (1998) Apolipoprotein E epsilon4 allele as a genetic risk factor for left ventricular failure in homozygous beta-thalassaemia. Blood 92(9):3455\u20133459","journal-title":"Blood"},{"issue":"20","key":"10663_CR40","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1161\/CIRCULATIONAHA.109.874487","volume":"120","author":"P Kirk","year":"2009","unstructured":"Kirk P, Roughton M, Porter JB et al (2009) Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassaemia major. Circulation 120(20):1961\u20131968","journal-title":"Circulation"},{"issue":"9","key":"10663_CR41","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1056\/NEJM199409013310903","volume":"331","author":"NF Olivieri","year":"1994","unstructured":"Olivieri NF, Nathan DG, MacMillan JH et al (1994) Survival in medically treated patients with homozygous beta-thalassaemia. N Engl J Med 331(9):574\u2013578","journal-title":"N Engl J Med"},{"issue":"11","key":"10663_CR42","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.cardfail.2010.05.009","volume":"16","author":"CJ Murphy","year":"2010","unstructured":"Murphy CJ, Oudit GY (2010) Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. J Card Fail 16(11):888\u2013900","journal-title":"J Card Fail"},{"issue":"1","key":"10663_CR43","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1161\/01.CIR.82.1.88","volume":"82","author":"P Spirito","year":"1990","unstructured":"Spirito P, Lupi G, Melevendi C, Vecchio C (1990) Restrictive diastolic abnormalities identified by Doppler echocardiography in patients with thalassaemia major. Circulation 82(1):88\u201394","journal-title":"Circulation"},{"issue":"3","key":"10663_CR44","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1161\/01.CIR.88.3.1127","volume":"88","author":"DT Kremastinos","year":"1993","unstructured":"Kremastinos DT, Tsiapras DP, Tsetsos GA, Rentoukas EI, Vretou HP, Toutouzas PK (1993) Left ventricular diastolic Doppler characteristics in beta-thalassaemia major. Circulation 88(3):1127\u20131135","journal-title":"Circulation"},{"issue":"2","key":"10663_CR45","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.euje.2006.02.004","volume":"8","author":"AM Hamdy","year":"2007","unstructured":"Hamdy AM (2007) Use of strain and tissue velocity imaging for early detection of regional myocardial dysfunction in patients with beta thalassaemia. Eur J Echocardiogr 8(2):102\u2013109","journal-title":"Eur J Echocardiogr"},{"issue":"1","key":"10663_CR46","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ajh.23581","volume":"89","author":"AG Kostopoulou","year":"2014","unstructured":"Kostopoulou AG, Tsiapras DP, Chaidaroglou AS, De Giannis DE, Farmakis D, Kremastinos DT (2014) The pathophysiological relationship and clinical significance of left atrial function and left ventricular diastolic dysfunction in \u03b2-thalassaemia major. Am J Hematol 89(1):13\u201318","journal-title":"Am J Hematol"},{"issue":"9","key":"10663_CR47","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1007\/s00277-023-05380-6","volume":"103","author":"D Patsourakos","year":"2024","unstructured":"Patsourakos D, Aggeli C, Dimitroglou Y et al (2024) Speckle tracking echocardiography and \u03b2-thalassaemia major: a systematic review. Ann Hematol 103(9):3335\u20133356","journal-title":"Ann Hematol"},{"issue":"6","key":"10663_CR48","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/jmri.20915","volume":"25","author":"MA Westwood","year":"2007","unstructured":"Westwood MA, Anderson LJ, Maceira AM et al (2007) Normalized left ventricular volumes and function in thalassaemia major patients with normal myocardial iron. J Magn Reson Imaging 25(6):1147\u20131151","journal-title":"J Magn Reson Imaging"},{"issue":"5","key":"10663_CR49","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1161\/CIRCULATIONAHA.116.022803","volume":"134","author":"A Abdel-Gadir","year":"2016","unstructured":"Abdel-Gadir A, Vorasettakarnkij Y, Ngamkasem H et al (2016) Ultrafast Magnetic Resonance Imaging for Iron Quantification in Thalassaemia Participants in the Developing World: The TIC-TOC Study. Circulation 134(5):432\u2013434","journal-title":"Circulation"},{"issue":"3","key":"10663_CR50","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/ehjqcco\/qcab089","volume":"8","author":"KM Medina","year":"2022","unstructured":"Medina KM, Abdel-Gadir A, Ganga K et al (2022) Use of rapid cardiac magnetic resonance imaging to guide chelation therapy in patients with transfusion-dependent thalassaemia in India: UMIMI study. Eur Heart J Qual Care Clin Outcomes 8(3):289\u2013297","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10663_CR51","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/ehjci\/jex012","volume":"19","author":"A Pepe","year":"2018","unstructured":"Pepe A, Pistoia L, Gamberini MR et al (2018) Prediction of cardiac complications for thalassaemia major in the widespread cardiac magnetic resonance era. Eur Heart J Cardiovasc Imaging 19:299\u2013309","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"2","key":"10663_CR52","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1007\/s00330-022-09120-8","volume":"33","author":"A Meloni","year":"2023","unstructured":"Meloni A, Pistoia L, Positano V et al (2023) Increased myocardial extracellular volume is associated with myocardial iron overload and heart failure in thalassaemia major. Eur Radiol 33(2):1266\u20131276","journal-title":"Eur Radiol"},{"key":"10663_CR53","doi-asserted-by":"crossref","unstructured":"Meloni A, Pistoia L, Gamberini MR et al (2023) Multi-parametric cardiac magnetic resonance for prediction of heart failure death in thalassaemia major. Diagnostics (Basel). ;13","DOI":"10.3390\/diagnostics13050890"},{"issue":"23","key":"10663_CR54","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1053\/euhj.2001.2822","volume":"22","author":"LJ Anderson","year":"2001","unstructured":"Anderson LJ, Holden S, Davis B et al (2001) Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 22(23):2171\u20132179","journal-title":"Eur Heart J"},{"issue":"13","key":"10663_CR55","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1093\/eurheartj\/ehq106","volume":"31","author":"F Alpendurada","year":"2010","unstructured":"Alpendurada F, Carpenter JP, Deac M et al (2010) Relation of myocardial T2* to right ventricular function in thalassaemia major. Eur Heart J 31(13):1648\u20131654","journal-title":"Eur Heart J"},{"issue":"3","key":"10663_CR56","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.113.002124","volume":"129","author":"G Derchi","year":"2014","unstructured":"Derchi G, Galanello R, Bina P et al (2014) Prevalence and risk factors for pulmonary arterial hypertension in a large group of beta-thalassaemia patients using right heart catheterization: a Webthal study. Circulation 129(3):338\u2013345","journal-title":"Circulation"},{"issue":"14","key":"10663_CR57","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.110.007641","volume":"123","author":"JP Carpenter","year":"2011","unstructured":"Carpenter JP, He T, Kirk P et al (2011) On T2* magnetic resonance and cardiac iron. Circulation 123(14):1519\u20131528","journal-title":"Circulation"},{"issue":"4","key":"10663_CR58","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.blre.2018.02.001","volume":"32","author":"MD Cappellini","year":"2018","unstructured":"Cappellini MD, Porter JB, Viprakasit V, Taher AT (2018) A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies? Blood Rev 32(4):300\u2013311","journal-title":"Blood Rev"},{"issue":"26","key":"10663_CR59","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1093\/eurheartj\/ehab851","volume":"43","author":"A Pepe","year":"2022","unstructured":"Pepe A, Pistoia L, Gamberini MR et al (2022) National networking in rare diseases and reduction of cardiac burden in thalassaemia major. Eur Heart J 43(26):2482\u20132492","journal-title":"Eur Heart J"},{"issue":"10","key":"10663_CR60","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1182\/blood-2013-04-497842","volume":"123","author":"DJ Pennell","year":"2014","unstructured":"Pennell DJ, Porter JB, Piga A et al (2014) A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in \u03b2-thalassaemia major (CORDELIA). Blood 123(10):1447\u20131454","journal-title":"Blood"},{"issue":"14","key":"10663_CR61","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1161\/CIRCULATIONAHA.106.648790","volume":"115","author":"MA Tanner","year":"2007","unstructured":"Tanner MA, Galanello R, Dessi C et al (2007) A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance. Circulation 115(14):1876\u20131884","journal-title":"Circulation"},{"issue":"1","key":"10663_CR62","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1532-429X-10-12","volume":"10","author":"MA Tanner","year":"2008","unstructured":"Tanner MA, Galanello R, Dessi C et al (2008) Combined chelation therapy in thalassaemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 10(1):12","journal-title":"J Cardiovasc Magn Reson"},{"issue":"3","key":"10663_CR63","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1365-2141.2004.05202.x","volume":"127","author":"LJ Anderson","year":"2004","unstructured":"Anderson LJ, Westwood MA, Holden S et al (2004) Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 127(3):348\u2013355","journal-title":"Br J Haematol"},{"issue":"9","key":"10663_CR64","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJM199409013310902","volume":"331","author":"GM Brittenham","year":"1994","unstructured":"Brittenham GM, Griffith PM, Nienhuis AW et al (1994) Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients With Thalassemia Major. N Engl J Med 331(9):567\u2013573","journal-title":"N Engl J Med"},{"issue":"9332","key":"10663_CR65","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S0140-6736(02)09740-4","volume":"360","author":"LJ Anderson","year":"2002","unstructured":"Anderson LJ, Wonke B, Prescott E et al (2002) Comparison of Effects of Oral Deferiprone and Subcutaneous Desferrioxamine on Myocardial Iron Concentrations and Ventricular Function in Beta-Thalassaemia. Lancet 360(9332):516\u2013520","journal-title":"Lancet"},{"issue":"9","key":"10663_CR66","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.1182\/blood-2005-07-2948","volume":"107","author":"DJ Pennell","year":"2006","unstructured":"Pennell DJ, Berdoukas V, Karagiorga M et al (2006) Randomized Controlled Trial of Deferiprone or Deferoxamine in Beta-Thalassemia Major Patients With Asymptomatic Myocardial Siderosis. Blood 107(9):3738\u20133744","journal-title":"Blood"},{"key":"10663_CR67","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1532-429X-13-34","volume":"13","author":"GC Smith","year":"2011","unstructured":"Smith GC, Alpendurada F, Carpenter JP et al (2011) Effect of Deferiprone or Deferoxamine on Right Ventricular Function in Thalassemia Major Patients With Myocardial Iron Overload. J Cardiovasc Magn Reson 13:34","journal-title":"J Cardiovasc Magn Reson"},{"issue":"12","key":"10663_CR68","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1182\/blood-2009-04-217455","volume":"115","author":"DJ Pennell","year":"2010","unstructured":"Pennell DJ, Porter JB, Cappellini MD et al (2010) Efficacy of Deferasirox in Reducing and Preventing Cardiac Iron Overload in Beta-Thalassemia. Blood 115(12):2364\u20132371","journal-title":"Blood"},{"issue":"1","key":"10663_CR69","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3324\/haematol.2010.031468","volume":"96","author":"DJ Pennell","year":"2011","unstructured":"Pennell DJ, Porter JB, Cappellini MD et al (2011) Continued Improvement in Myocardial T2* Over Two Years of Deferasirox Therapy in \u03b2-Thalassemia Major Patients With Cardiac Iron Overload. Haematologica 96(1):48\u201354","journal-title":"Haematologica"},{"issue":"6","key":"10663_CR70","doi-asserted-by":"publisher","first-page":"842","DOI":"10.3324\/haematol.2011.049957","volume":"97","author":"DJ Pennell","year":"2012","unstructured":"Pennell DJ, Porter JB, Cappellini MD et al (2012) Deferasirox for Up to 3 Years Leads to Continued Improvement of Myocardial T2* in Patients With \u03b2-Thalassemia Major. Haematologica 97(6):842\u2013848","journal-title":"Haematologica"},{"issue":"2","key":"10663_CR71","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/ejh.12793","volume":"98","author":"PJ Ho","year":"2017","unstructured":"Ho PJ, Tay L, Teo J et al (2017) Cardiac Iron Load and Function in Transfused Patients Treated With Deferasirox (The MILE Study). Eur J Haematol 98(2):97\u2013105","journal-title":"Eur J Haematol"},{"issue":"5","key":"10663_CR72","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/bjh.15595","volume":"183","author":"A Pepe","year":"2018","unstructured":"Pepe A, Meloni A, Pistoia L et al (2018) MRI Multicentre Prospective Survey in Thalassaemia Major Patients Treated With Deferasirox Versus Deferiprone and Desferrioxamine. Br J Haematol 183(5):783\u2013795","journal-title":"Br J Haematol"},{"issue":"12","key":"10663_CR73","doi-asserted-by":"publisher","first-page":"e82662","DOI":"10.1371\/journal.pone.0082662","volume":"8","author":"S Xia","year":"2013","unstructured":"Xia S, Zhang W, Huang L, Jiang H (2013) Comparative Efficacy and Safety of Deferoxamine, Deferiprone and Deferasirox on Severe Thalassemia: A Meta-Analysis of 16 Randomized Controlled Trials. PLoS ONE 8(12):e82662","journal-title":"PLoS ONE"},{"key":"10663_CR74","doi-asserted-by":"crossref","unstructured":"Fisher SA, Brunskill SJ, Doree C et al (2013) Desferrioxamine Mesylate for Managing Transfusional Iron Overload in People With Transfusion-Dependent Thalassaemia. Cochrane Database Syst Rev. ;(8):CD004450","DOI":"10.1002\/14651858.CD004450.pub3"},{"issue":"12","key":"10663_CR75","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1182\/blood-2016-06-721183","volume":"128","author":"JL Fernandes","year":"2016","unstructured":"Fernandes JL, Loggetto SR, Verissimo MP et al (2016) A randomized trial of amlodipine in addition to standard chelation therapy in patients with thalassaemia major. Blood 128(12):1555\u20131561","journal-title":"Blood"},{"key":"10663_CR76","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.2147\/DDDT.S211630","volume":"13","author":"A Khaled","year":"2019","unstructured":"Khaled A, Salem HA, Assy N et al (2019) A randomized controlled trial evaluating the effects of amlodipine on myocardial iron deposition in pediatric patients with thalassaemia major. Drug Des Devel Ther 13:2427\u20132436","journal-title":"Drug Des Devel Ther"},{"issue":"6","key":"10663_CR77","doi-asserted-by":"publisher","first-page":"e29564","DOI":"10.1002\/pbc.29564","volume":"69","author":"V Gupta","year":"2022","unstructured":"Gupta V, Kumar A, Saini I et al (2022) Comparison of the effects of calcium channel blockers plus iron chelation therapy versus chelation therapy only on iron overload in children and young adults with TDT. Pediatr Blood Cancer 69(6):e29564","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10663_CR78","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/ejh.12977","volume":"99","author":"A Eghbali","year":"2017","unstructured":"Eghbali A, Shokri P, Afzal RR, Hasanpour H (2017) A randomized, controlled study evaluating effects of amlodipine addition to chelators to reduce iron loading in patients with thalassaemia major. Eur J Haematol 99(6):577\u2013581","journal-title":"Eur J Haematol"},{"issue":"4","key":"10663_CR79","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/ejh.13919","volume":"110","author":"Y Soliman","year":"2023","unstructured":"Soliman Y, Abdelrahman HA, Moustafa AH et al (2023) Efficacy and safety of calcium channel blockers in preventing cardiac siderosis in thalassaemia patients: an updated meta-analysis with trial sequential analysis. Eur J Haematol 110(4):414\u2013425","journal-title":"Eur J Haematol"},{"issue":"11","key":"10663_CR80","first-page":"CD011626","volume":"11","author":"ZA Padhani","year":"2023","unstructured":"Padhani ZA, Ladiwala ZFR, Salam RA, Bhutta ZA (2023) Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia. Cochrane Database Syst Rev 11(11):CD011626","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10663_CR81","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0002-9343(01)00879-8","volume":"111","author":"DT Kremastinos","year":"2001","unstructured":"Kremastinos DT, Tsetsos GA, Tsiapras DP, Karavolias GK, Ladis VA, Kattamis CA (2001) Heart failure in beta thalassaemia: a 5-year follow-up study. Am J Med 111(5):349\u2013354","journal-title":"Am J Med"},{"issue":"3","key":"10663_CR82","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1161\/CIR.0b013e31829b2be6","volume":"128","author":"DJ Pennell","year":"2013","unstructured":"Pennell DJ, Udelson JE, Arai AE et al (2013) Cardiovascular function and treatment in \u03b2-thalassaemia major: a consensus statement from the American Heart Association. Circulation 128(3):281\u2013308","journal-title":"Circulation"},{"issue":"36","key":"10663_CR83","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder IC, Rienstra M, Bunting KV et al (2024) 2024 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 45(36):3314\u20133414","journal-title":"Eur Heart J"},{"issue":"13","key":"10663_CR84","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1056\/NEJMoa1910182","volume":"382","author":"MD Cappellini","year":"2020","unstructured":"Cappellini MD, Viprakasit V, Taher AT et al (2020) A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent \u03b2-Thalassaemia. N Engl J Med 382(13):1219\u20131231","journal-title":"N Engl J Med"},{"issue":"3","key":"10663_CR85","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1016\/S2352-3026(24)00376-4","volume":"12","author":"MD Cappellini","year":"2025","unstructured":"Cappellini MD, Taher AT, Piga A et al (2025) Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent \u03b2-thalassaemia (BELIEVE): final results from a phase 3 randomised trial. Lancet Haematol 12(3):e180\u2013e189","journal-title":"Lancet Haematol"},{"key":"10663_CR86","unstructured":"Label FDA (2026) AQVESME (mitapivat). Prescribing Information. U.S. Food and Drug Administration"},{"issue":"5","key":"10663_CR87","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa2113206","volume":"386","author":"F Locatelli","year":"2022","unstructured":"Locatelli F, Thompson AA, Kwiatkowski JL et al (2022) Betibeglogene autotemcel gene therapy for non-\u03b20\/\u03b20 genotype \u03b2-thalassaemia. N Engl J Med 386(5):415\u2013427","journal-title":"N Engl J Med"},{"issue":"18","key":"10663_CR88","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","volume":"390","author":"F Locatelli","year":"2024","unstructured":"Locatelli F, Lang P, Wall D et al (2024) Exagamglogene autotemcel for transfusion-dependent \u03b2-thalassaemia. N Engl J Med 390(18):1663\u20131676","journal-title":"N Engl J Med"},{"issue":"4","key":"10663_CR89","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41422-019-0150-y","volume":"29","author":"M Conrad","year":"2019","unstructured":"Conrad M, Proneth B (2019) Broken hearts: Iron overload, ferroptosis and cardiomyopathy. Cell Res 29(4):263\u2013264","journal-title":"Cell Res"},{"issue":"8","key":"10663_CR90","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s00210-022-02243-1","volume":"395","author":"S Ma","year":"2022","unstructured":"Ma S, He LL, Zhang GR et al (2022) Canagliflozin mitigates ferroptosis and ameliorates heart failure in rats with preserved ejection fraction. Naunyn Schmiedebergs Arch Pharmacol 395(8):945\u2013962","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10663_CR91","doi-asserted-by":"publisher","first-page":"1011669","DOI":"10.3389\/fendo.2022.1011669","volume":"13","author":"S Du","year":"2022","unstructured":"Du S, Shi H, Xiong L, Wang P, Shi Y (2022) Canagliflozin mitigates ferroptosis and improves myocardial oxidative stress in mice with diabetic cardiomyopathy. Front Endocrinol (Lausanne) 13:1011669","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"10663_CR92","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.7150\/thno.75121","volume":"12","author":"L Ma","year":"2022","unstructured":"Ma L, Zou R, Shi W et al (2022) SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia\/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin pathways. Theranostics 12(11):5034\u20135050","journal-title":"Theranostics"},{"key":"10663_CR93","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/978-3-031-92033-2_26","volume":"1480","author":"A Nai","year":"2025","unstructured":"Nai A, Silvestri L, Asperti M, Vinchi F (2025) Current landscape of hepcidin therapeutics. Adv Exp Med Biol 1480:399\u2013418","journal-title":"Adv Exp Med Biol"},{"issue":"16","key":"10663_CR94","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1182\/blood-2017-11-737411","volume":"131","author":"C Casu","year":"2018","unstructured":"Casu C, Nemeth E, Rivella S (2018) Hepcidin agonists as therapeutic tools. Blood 131(16):1790\u20131794","journal-title":"Blood"},{"issue":"12","key":"10663_CR95","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/S2468-1253(23)00250-9","volume":"8","author":"KV Kowdley","year":"2023","unstructured":"Kowdley KV, Modi NB, Peltekian K, Vierling JM, Ferris C, Valone FH, Gupta S (2023) Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial. Lancet Gastroenterol Hepatol 8(12):1118\u20131128","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"17","key":"10663_CR96","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood-2015-07-658419","volume":"126","author":"L Kautz","year":"2015","unstructured":"Kautz L, Jung G, Du X et al (2015) Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of \u03b2-thalassaemia. Blood 126(17):2031\u20132037","journal-title":"Blood"},{"issue":"3","key":"10663_CR97","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/ajh.26798","volume":"98","author":"GL Forni","year":"2023","unstructured":"Forni GL, Gianesin B, Musallam KM et al (2023) Overall and complication-free survival in a large cohort of patients with \u03b2-thalassaemia major followed over 50 years. Am J Hematol 98(3):381\u2013387","journal-title":"Am J Hematol"},{"issue":"1","key":"10663_CR98","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/ejh.13410","volume":"105","author":"D Farmakis","year":"2020","unstructured":"Farmakis D, Giakoumis A, Angastiniotis M, Eleftheriou A (2020) The changing epidemiology of the ageing thalassaemia populations: a position statement of the Thalassaemia International Federation. Eur J Haematol 105(1):16\u201323","journal-title":"Eur J Haematol"},{"issue":"4","key":"10663_CR99","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.healun.2004.02.009","volume":"24","author":"AE Caines","year":"2005","unstructured":"Caines AE, Kpodonu J, Massad MG et al (2005) Cardiac transplantation in patients with iron overload cardiomyopathy. J Heart Lung Transpl 24(4):486\u2013488","journal-title":"J Heart Lung Transpl"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10663-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-026-10663-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10663-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T08:02:14Z","timestamp":1786089734000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-026-10663-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10663"],"URL":"https:\/\/doi.org\/10.1007\/s10741-026-10663-x","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"5 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"91"}}